Adjuvant T-DM1 Approaches EU Approval for HER2+ Early Breast Cancer

November 15, 2019 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease (breast and/or lymph nodes) following neoadjuvant taxane-based chemotherapy and HER2-targeted therapy. The CHMP based its recommendation on findings … (leggi tutto)